141 related articles for article (PubMed ID: 19371427)
1. CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors.
Chen CC; Kennedy RD; Sidi S; Look AT; D'Andrea A
Mol Cancer; 2009 Apr; 8():24. PubMed ID: 19371427
[TBL] [Abstract][Full Text] [Related]
2. Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway.
Wang X; Kennedy RD; Ray K; Stuckert P; Ellenberger T; D'Andrea AD
Mol Cell Biol; 2007 Apr; 27(8):3098-108. PubMed ID: 17296736
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
4. Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach.
Giridhara Prema S; Chandrasekaran J; Kanekar S; George M; Prasad TSK; Raju R; Dagamajalu S; Balaya RDA
OMICS; 2024 Jan; 28(1):8-23. PubMed ID: 38190280
[TBL] [Abstract][Full Text] [Related]
5. The p53 DNA damage response and Fanconi anemia DNA repair pathway protect against acetaldehyde-induced replication stress in esophageal keratinocytes.
Peake JD; Horne KI; Noguchi C; Gilligan JP; Noguchi E
Cell Cycle; 2023 Sep; 22(18):2088-2096. PubMed ID: 37749911
[TBL] [Abstract][Full Text] [Related]
6. Inherited DNA Repair Defects Disrupt the Structure and Function of Human Skin.
Ruiz-Torres S; Brusadelli MG; Witte DP; Wikenheiser-Brokamp KA; Sauter S; Nelson AS; Sertorio M; Chlon TM; Lane A; Mehta PA; Myers KC; Bedard MC; Pal B; Supp DM; Lambert PF; Komurov K; Kovacic MB; Davies SM; Wells SI
Cell Stem Cell; 2021 Mar; 28(3):424-435.e6. PubMed ID: 33232662
[TBL] [Abstract][Full Text] [Related]
7. BRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).
Pongas G; Kim MK; Min DJ; House CD; Jordan E; Caplen N; Chakka S; Ohiri J; Kruhlak MJ; Annunziata CM
Oncotarget; 2017 Aug; 8(31):51402-51415. PubMed ID: 28881656
[TBL] [Abstract][Full Text] [Related]
8. Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control.
Concannon K; Morris BB; Gay CM; Byers LA
Mol Cell; 2023 Mar; 83(5):660-680. PubMed ID: 36669489
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of the Fanconi anaemia pathway as potential antitumour agents for ovarian cancer.
Taylor SJ; Arends MJ; Langdon SP
Explor Target Antitumor Ther; 2020; 1(1):26-52. PubMed ID: 36046263
[TBL] [Abstract][Full Text] [Related]
10. The RPA inhibitor HAMNO sensitizes Fanconi anemia pathway-deficient cells.
Jang SW; Kim JM
Cell Cycle; 2022 Jul; 21(14):1468-1478. PubMed ID: 35506981
[TBL] [Abstract][Full Text] [Related]
11. FANCI functions as a repair/apoptosis switch in response to DNA crosslinks.
Shah RB; Kernan JL; van Hoogstraten A; Ando K; Li Y; Belcher AL; Mininger I; Bussenault AM; Raman R; Ramanagoudr-Bhojappa R; Huang TT; D'Andrea AD; Chandrasekharappa SC; Aggarwal AK; Thompson R; Sidi S
Dev Cell; 2021 Aug; 56(15):2207-2222.e7. PubMed ID: 34256011
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Predisposition Genes and Synthetic Lethality.
Neiger HE; Siegler EL; Shi Y
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070674
[No Abstract] [Full Text] [Related]
13. Acceleration or Brakes: Which Is Rational for Cell Cycle-Targeting Neuroblastoma Therapy?
Ando K; Nakagawara A
Biomolecules; 2021 May; 11(5):. PubMed ID: 34069817
[TBL] [Abstract][Full Text] [Related]
14. SIK2 kinase synthetic lethality is driven by spindle assembly defects in FANCA-deficient cells.
Chan KK; Abdul-Sater Z; Sheth A; Mitchell DK; Sharma R; Edwards DM; He Y; Nalepa G; Rhodes SD; Clapp DW; Sierra Potchanant EA
Mol Oncol; 2022 Feb; 16(4):860-884. PubMed ID: 34058059
[TBL] [Abstract][Full Text] [Related]
15. Fanconi Anemia DNA Repair Pathway as a New Mechanism to Exploit Cancer Drug Resistance.
Ghosal K; Agatemor C; Han RI; Ku AT; Thomas S; Mukherjee S
Mini Rev Med Chem; 2020; 20(9):779-787. PubMed ID: 31902358
[TBL] [Abstract][Full Text] [Related]
16. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
17. Targeting the DNA Damage Response in OSCC with TP53 Mutations.
Lindemann A; Takahashi H; Patel AA; Osman AA; Myers JN
J Dent Res; 2018 Jun; 97(6):635-644. PubMed ID: 29489434
[TBL] [Abstract][Full Text] [Related]
18. Fanconi anaemia and cancer: an intricate relationship.
Nalepa G; Clapp DW
Nat Rev Cancer; 2018 Mar; 18(3):168-185. PubMed ID: 29376519
[TBL] [Abstract][Full Text] [Related]
19. Suppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.
Dai CH; Wang Y; Chen P; Jiang Q; Lan T; Li MY; Su JY; Wu Y; Li J
Sci Rep; 2017 Nov; 7(1):15031. PubMed ID: 29118324
[TBL] [Abstract][Full Text] [Related]
20. ATR/CHK1 inhibitors and cancer therapy.
Qiu Z; Oleinick NL; Zhang J
Radiother Oncol; 2018 Mar; 126(3):450-464. PubMed ID: 29054375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
